Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199171 | 1.00 | PTPN1 (0.44) | PTPN1CASP3RENMDM4TP53 | |
| SCHEMBL1411037 | 0.95 | CASP3 (0.46) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL1410927 | 0.95 | CASP3 (0.46) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL1409105 | 0.93 | CTSL (0.41) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL1409102 | 0.93 | CTSL (0.41) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL2197679 | 0.93 | CASP3 (0.48) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL2197673 | 0.93 | CASP3 (0.48) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL2193892 | 0.92 | CASP3 (0.43) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL2193899 | 0.92 | CASP3 (0.43) | PTPN1CASP3MDM4TP53 | |
| SCHEMBL12509956 | 0.90 | PTPN1 (0.45) | PTPN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888097-B1 | FK 228 DERIVATES AS HDAC INHIBITORS | UNIV SOUTHAMPTON (GB) | 2014-03-05 | — | — | EP | disclosed |
| US-7977304-B2 | FK 228 derivates as HDAC inhibitors | UNIVERSITY OF SOUTHAMPTON HIGHFIELD (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090131390-A1 | FK 228 derivates as HDAC inhibitors | UNIVERSITY OF SOUTHAMPTON (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1888097-A1 | FK 228 DERIVATES AS HDAC INHIBITORS | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006129105-A1 | FK 228 DERIVATES AS HDAC INHIBITORS | UNIVERSITY OF SOUTHAMPTON (GB) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131390-A1 | FK 228 derivates as HDAC inhibitors | HDAC1, HDAC8, HDAC11 | PTPN1 4064/4885CASP3 466/4885REN 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.